



FAS inhibitor | BI 99179

Table of contents

Summary	2
Chemical Structure	2
Highlights	3
Target information	3
<i>In vitro</i> activity	4
<i>In vitro</i> DMPK and CMC parameters	5
<i>In vivo</i> DMPK parameters	5
<i>In vivo</i> pharmacology	6
Negative control	7
Selectivity	8
Co-crystal structure of the BI probe compound and the target protein	8
Reference molecule(s)	8
Summary	9
Supplementary data	9
References	9

Summary

Our FAS *in vivo* tool compound BI 99179 is characterised by high potency, good selectivity and significant peripheral and central exposure upon oral administration in rats.

Due to the observed subchronic adverse effects *in vivo* the project was not further pursued for obesity.

We hope that the availability of this molecule together with a negative *in vitro* control (BI 99990) will stimulate further research in the field of disorders related to lipid metabolism e.g. acne.

Supplementary data

Selectivity data can be downloaded free of charge from this site.

References

1. Jörg T. Kley, Jürgen Mack, Bradford Hamilton, Stefan Scheuerer, and Norbert Redemann Discovery of BI 99179, a potent and selective inhibitor of type I fatty acid synthase with central exposure *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5924-5927. [doi:10.1016/j.bmcl.2011.07.083](https://doi.org/10.1016/j.bmcl.2011.07.083), [PubMed](#).
2. Richard Flavin, Stephane Peluso, Paul L. Nguyen, and Massimo Loda Fatty acid synthase as a potential therapeutic target in cancer *Future Oncol.* **2010**, *6*, 551-562. [doi: 10.2217/fon.10.11](https://doi.org/10.2217/fon.10.11), [PubMed](#).
3. Steven J. Kridel, W Todd Lowther, and Charles W. Pemble IV Fatty acid synthase inhibitors: new directions for oncology *Expert Opin. Invest. Drugs* **2007**, *16*, 1817-1829. [DOI: 10.1517/13543784.16.11.1817](https://doi.org/10.1517/13543784.16.11.1817), [PubMed](#).
4. Thomas M. Loftus *et al* Reduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors *Science* **2000**, *288*, 2379. [DOI: 10.1126/science.288.5475.2379](https://doi.org/10.1126/science.288.5475.2379), [PubMed](#).
5. D'Arcangelis, A. D., *et al.* U.S. Patent 53631, 2005.
6. Timm Maier, Marc Leibundgut, and Nenad Ban The Crystal Structure of a Mammalian Fatty Acid Synthase *Science* **2008**, *321*, 1315-1322. [DOI: 10.1126/science.1161269](https://doi.org/10.1126/science.1161269), [PubMed](#).
7. Mary Ann Hardwicke, *et al.* A human fatty acid synthase inhibitor binds β -ketoacyl reductase in the keto-substrate site *Nature Chemical Biology* **2014**, *10*, 774-779. [doi:10.1038/nchembio.1603](https://doi.org/10.1038/nchembio.1603), [PubMed](#).
8. Natthida Tongluan, *et al.* Involvement of fatty acid synthase in dengue virus infection *Virology Journal* **2017**, *14*, 28 [DOI: 10.1186/s12985-017-0685-9](https://doi.org/10.1186/s12985-017-0685-9), [PubMed](#).

9. Hitomi Okamura, Yasunori Nio, Yuichi Akahori, Sulyi Kim, Koichi Watashi, Takaji Wakita, Makoto Hijikata Fatty acid biosynthesis is involved in the production of hepatitis B virus particles *Biochemical and Biophysical Research Communications* **2016**, 475, 87-92 [DOI: 10.1016/j.bbrc.2016.05.043](#), [PubMed](#).
10. Yamini M. Ohol, Zhaoti Wang, George Kemble, Gregory Duke Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses *PLoS One* **2015**, 10(12) [DOI: 10.1371/journal.pone.0144648](#), [PubMed](#).
11. Suzanne F. Jones, Jeffrey R. Infante Molecular Pathways: Fatty Acid Synthase *Clin. Cancer Res.* **2015**, 21, 5434-5438 [DOI: 10.1158/1078-0432.CCR-15-0126](#); [PubMed](#).